parecoxib has been researched along with amodiaquine in 1 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (amodiaquine) | Trials (amodiaquine) | Recent Studies (post-2010) (amodiaquine) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 1,455 | 315 | 473 |
| Protein | Taxonomy | parecoxib (IC50) | amodiaquine (IC50) |
|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | 4.7 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 5.15 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.99 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 0.99 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merk, D; Willems, S | 1 |
1 review(s) available for parecoxib and amodiaquine
| Article | Year |
|---|---|
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
Topics: Chemistry, Pharmaceutical; Humans; Ligands; Nuclear Receptor Subfamily 4, Group A, Member 2; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2022 |